AU2002235520A1 - Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer - Google Patents

Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer

Info

Publication number
AU2002235520A1
AU2002235520A1 AU2002235520A AU2002235520A AU2002235520A1 AU 2002235520 A1 AU2002235520 A1 AU 2002235520A1 AU 2002235520 A AU2002235520 A AU 2002235520A AU 2002235520 A AU2002235520 A AU 2002235520A AU 2002235520 A1 AU2002235520 A1 AU 2002235520A1
Authority
AU
Australia
Prior art keywords
uroguanylin
cyclooxygenase
inhibition
intestinal cancer
inhibitor combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002235520A
Inventor
Jaime L. Masferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2002235520A1 publication Critical patent/AU2002235520A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002235520A 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer Abandoned AU2002235520A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26595501P 2001-02-02 2001-02-02
US60/265,955 2001-02-02
PCT/US2002/003201 WO2002062369A2 (en) 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer

Publications (1)

Publication Number Publication Date
AU2002235520A1 true AU2002235520A1 (en) 2002-08-19

Family

ID=23012573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002235520A Abandoned AU2002235520A1 (en) 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer

Country Status (5)

Country Link
EP (1) EP1365753A2 (en)
JP (1) JP2004521123A (en)
AU (1) AU2002235520A1 (en)
CA (1) CA2435835A1 (en)
WO (1) WO2002062369A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1379224T4 (en) 2001-03-29 2013-12-02 Synergy Pharmaceuticals Inc Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1594517B1 (en) * 2003-01-28 2007-06-20 Microbia, Inc. Compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
EP1644021B1 (en) 2003-06-13 2012-08-22 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8207295B2 (en) 2008-06-04 2012-06-26 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
LT2328601T (en) 2008-08-15 2020-04-27 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
EP2341898A2 (en) * 2008-09-04 2011-07-13 Ironwood Pharmaceuticals, Inc. Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
DK2603232T3 (en) 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc STABLE FORMS OF LINACLOTID
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2621509A4 (en) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc Formulations of guanylate cyclase c agonists and methods of use
MX347354B (en) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders.
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation

Also Published As

Publication number Publication date
CA2435835A1 (en) 2002-08-15
WO2002062369A3 (en) 2003-08-28
EP1365753A2 (en) 2003-12-03
JP2004521123A (en) 2004-07-15
WO2002062369A2 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
AU2002235520A1 (en) Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
AU2002339348A1 (en) Inhibition of STAT-1
AU2002219472A1 (en) Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2002252456A1 (en) Combination treatment of pancreatic cancer
AU2003234257A1 (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
HK1080069A1 (en) Nitrooxyderivatives of cyclooxygenase-2 inhibitors
AU2002328952A1 (en) Irinotecan for treatment of cancer
AU2002312566A1 (en) Methods of inhibiting amyloid toxicity
AU2002341542A1 (en) Transcription factors of cereals
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
AU2003222197A1 (en) Inhibition of rna function
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2001288360A1 (en) Genomics-assisted rapid identification of targets
AU2003260778A1 (en) Treatment of pipes
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2001245414A1 (en) Treatment of allergies
AU7957000A (en) Cyclooxygenase-2 expression inhibitors
AU2002214868A1 (en) Therapeutic oligonucleotides of reduced toxicity
AU2002311845A1 (en) Methods of treating intestinal inflammation
AU2002366195A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2003284787A1 (en) Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor
AU2002305868A1 (en) Inhibitors of reggamma
AU2003299137A1 (en) Inhibition of metallo-beta-lactamase
AU2003303625A1 (en) Combination of reboxetine and a cyclooxygenase-2 inhibitor
GB0100151D0 (en) Methods of sputtering

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase